Effects of 5-methoxytryptophan on cardiac structure and functions in a rat model of diabetic cardiomyopathy

Table 3 Changes in cardiac diastolic function after 8 days, 16 days, and 32 days of 5-methoxytryptophan treatment in a rat model of diabetic cardiomyopathy

Treatment group	Day 8	P value	Day 16	P value	Day 32	P value
ΔE/e'
DCM (control)	-4.63 ± 12.06		-6.83 ± 9.98		-10.46 ± 16.38
DCM + 5-MTP 25 mg/kg	1.72 ± 4.96	0.269	-2.27 ± 13.41	0.527	-1.82 ± 11.76	0.299
DCM + 5-MTP 50 mg/kg	-0.16 ± 6.32	0.431	-3.46 ± 9.48	0.638	4.73 ± 5.45	0.081
DCM + 5-MTP 100 mg/kg	1.53 ± 5.47	0.283	-1.13 ± 4.60	0.430	4.18 ± 8.48	0.091
P for treatment vs control		0.639		0.861		0.248
ΔE/A
DCM (control)	0.09 ± 0.92		-0.09 ± 0.83		-0.31 ± 0.11
DCM + 5-MTP 25 mg/kg	-0.40 ± 0.35	0.296	-0.30 ± 1.87	0.801	0.66 ± 0.29	0.003a
DCM + 5-MTP 50 mg/kg	-0.07 ± 0.25	0.730	0.34 ± 0.54	0.590	0.01 ± 0.29	0.264
DCM + 5-MTP 100 mg/kg	0.05 ± 0.62	0.936	0.25 ± 0.60	0.669	-0.06 ± 0.62	0.376
P for treatment vs control		0.693		0.834		0.020a

^aP < 0.05.

Normally distributed data are presented as mean ± SD and analyzed using one-way analysis of variance; non-normally distributed numerical data are presented as median (minimum-maximum) and analyzed using the Kruskal-Wallis test. Comparisons between the control group and treatment groups were performed using post hoc least significant difference for normally distributed data and pairwise Bonferroni testing for non-normally distributed data. 5-MTP: 5-Methoxytryptophan; DCM: Diabetic cardiomyopathy.